

WHO Drug Information

Contents

General Policy Topics

- Meta-analysis: a reliable technique for therapeutic audit? 171

Personal Perspectives

- Address to International Federation of Pharmaceutical Manufacturers Associations Assembly: Dr Hiroshi Nakajima 173

Reports on Individual Drugs

- Mifepristone in early termination of pregnancy 176
 Ditiocarb sodium in HIV infection 178
 Passive immunoneutralization of HIV 179
 Naloxone infusion in septic shock 180
 Low-dose diuretics in hypertension 180
 Digoxin and xamoterol in chronic heart failure 181
 Trimethoprim/sulfamethoxazole or penicillins in childhood pneumonia? 182
 Retinoids: control of cutaneous cancer 183
 Mianserin, blood disorders and suicide attempts 184
 Ginseng implicated in muscle damage? 184
 Mass treatment of schistosomiasis with praziquantel 184
 Acetylsalicylic acid and bleeding peptic ulcer in the elderly 185
 Amiodarone-induced hyperthyroidism and autoimmunity 186
 Scleroderma and silicone implants 186

General Information

- Adverse effects of radiopharmaceuticals 187
 Cardiovascular drugs remain the prime target for research 187
 Substandard and counterfeit medicines: a daunting problem 187
 Drug-related adverse effects: the limitations of inferential reasoning 188
 The cost of cardiovascular disease: beta blockers after cardiac infarction 188

- Postmarketing surveillance:
 industry-sponsored studies 189
 Cost of diabetic care 190
 Development of indigenous drugs 190
 Heart failure: contemporary trends 190

Regulatory Matters

Drugs for Human Use

- Anti-asthmatic drugs containing methyl-xanthines 192
 Cell therapy: withdrawal of branded products 192
 Cervical cap approved 192
 Drug withdrawals: Pakistan 193
 Electrical muscle stimulators: controlled indications and labelling 193
 Freons: import and manufacture prohibited 193
 Intrauterine contraceptive device: safety considerations 194
 Pyrrolizidine alkaloids and liver damage 194
 Sulfacarbamide withdrawal 194
 Vaccine-induced injury: statutory reporting requirements 195
 Update on the WHO Certification Scheme 195

Veterinary Drugs

- Hormones: restricted use in food-producing animals 195
 Drug residues in meat and dairy products 196

Advisory Notices

- Amoxicillin + clavulanic acid: cases of jaundice 197
 Angiotensin-converting enzyme blocking agents: fetotoxicity 197
 Fluoride content of dentifrices 197
 Clofibrate and muscle disorders 197
 Cytostatics: handling precautions 198
 Ergot alkaloids: dangers of post-operative use 198
 Evening primrose oil and epilepsy 198
 Fructose intolerance 198
 Lipid-lowering drugs: proof of efficacy 199
 Oral contraceptives: high estrogen preparations discouraged 199

Contents *(continued)*

Essential Drugs

Protozoan intestinal infections

Amoebiasis a major cause of death from parasitic intestinal disease	200
Giardiasis	201
Diloxanide	201
Metronidazole	202
Dehydroemetine	203
Chloroquine	204

Newly Registered Products	206
----------------------------------	-----

Recent Publications

Ethical criteria for medicinal drug promotion	208
Good manufacturing practices of Japan: third edition	208
British Pharmacopoeia 1988	208

Proposed International Nonproprietary Names: List 60	209
---	-----